Javascript must be enabled to continue!
Relation between Interleukin-6, Interleukin-10 and Interleukin-2 Receptor and mortality in Severely Ill COVID-19 patients
View through CrossRef
Objective: To investigate the relation involving soluble interleukin-2 receptor, interleukin-6 and interleukin-10 in hospitalised patients with severe coronavirus disease-2019 infection.Methods: This single-centre cohort study was conducted at the Kafrelshiekh University Hospital, Egypt, from January to June 2022, and included all patients of either gender who were hospitalised with severe infection with the coronavirus disease-2019 isolation ward. Chemiluminescence immunoassay method was used to measure levels of procalcitonin, ferritin, soluble interleukin-2 receptor, interleukin-6 and interleukin-10. Data was analysed using SPSS version. 25Results: Of the 250 patients with median age 57.5 years (interquartile range: 45.8-66.0 years), 147(59%) were males and 103(41%) were females. Of them, 102(40.8%) patients died; 68(66.7%) males, 34(33.3%) females, median age 60.0 years (interquartile range: 48.8-70.0). Among the 148(59.2%) survivors, 79(53.4%) were males and 69(46.6%) were females, while the overall median age was 55.0 years (interquartile range: 41.5-65.8 years). The survivors had significantly lower levels of soluble interleukin-2 receptor, interleukin-6 and interleukin-10 (p<0.001). Correlation analysis identified significant positive correlation between IL-2R, IL-6 and IL-10 levels and almost all the inflammatoryand coagulation parameters, including C-reactive protein, lactate dehydrogenase, procalcitonin, ferritin, D-dimer and fibrinogen (p<0.05).Conclusion: Elevated levels of soluble interleukin-2 receptor, interleukin-6 and interleukin-10 were found to be associated with greater risk of mortality in coronavirus disease-2019 patients.Keywords: Interleukin-6, Interleukin-10, Procalcitonin, Fibrin fragment D, COVID-19, Luminescence, Interleukin-2, Immunoassay, Fibrinogen, Ferritins
Title: Relation between Interleukin-6, Interleukin-10 and Interleukin-2 Receptor and mortality in Severely Ill COVID-19 patients
Description:
Objective: To investigate the relation involving soluble interleukin-2 receptor, interleukin-6 and interleukin-10 in hospitalised patients with severe coronavirus disease-2019 infection.
Methods: This single-centre cohort study was conducted at the Kafrelshiekh University Hospital, Egypt, from January to June 2022, and included all patients of either gender who were hospitalised with severe infection with the coronavirus disease-2019 isolation ward.
Chemiluminescence immunoassay method was used to measure levels of procalcitonin, ferritin, soluble interleukin-2 receptor, interleukin-6 and interleukin-10.
Data was analysed using SPSS version.
25Results: Of the 250 patients with median age 57.
5 years (interquartile range: 45.
8-66.
0 years), 147(59%) were males and 103(41%) were females.
Of them, 102(40.
8%) patients died; 68(66.
7%) males, 34(33.
3%) females, median age 60.
0 years (interquartile range: 48.
8-70.
0).
Among the 148(59.
2%) survivors, 79(53.
4%) were males and 69(46.
6%) were females, while the overall median age was 55.
0 years (interquartile range: 41.
5-65.
8 years).
The survivors had significantly lower levels of soluble interleukin-2 receptor, interleukin-6 and interleukin-10 (p<0.
001).
Correlation analysis identified significant positive correlation between IL-2R, IL-6 and IL-10 levels and almost all the inflammatoryand coagulation parameters, including C-reactive protein, lactate dehydrogenase, procalcitonin, ferritin, D-dimer and fibrinogen (p<0.
05).
Conclusion: Elevated levels of soluble interleukin-2 receptor, interleukin-6 and interleukin-10 were found to be associated with greater risk of mortality in coronavirus disease-2019 patients.
Keywords: Interleukin-6, Interleukin-10, Procalcitonin, Fibrin fragment D, COVID-19, Luminescence, Interleukin-2, Immunoassay, Fibrinogen, Ferritins.
Related Results
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus , is causing a serious worldwide COVID-19 pandemic. The emergence of strains with rapid spread and...
Correlation of COVID-19 Mortality with Clinical Parameters in an Urban and Suburban Nursing Home Population
Correlation of COVID-19 Mortality with Clinical Parameters in an Urban and Suburban Nursing Home Population
Abstract
Importance and Objective
COVID-19 has a high mortality rate amongst nursing home populations (26.4% nationally and 28....
Long COVID Treatment No Silver Bullets, Only a Few Bronze BBs
Long COVID Treatment No Silver Bullets, Only a Few Bronze BBs
Long COVID is the consequence of having had COVID. Long COVID has many other names including Long-haul COVID, Post-COVID conditions (PCC), Post-COVID-19 syndrome, Post-acute seque...
Long COVID Treatment No Silver Bullets, Only a Few Bronze BBs
Long COVID Treatment No Silver Bullets, Only a Few Bronze BBs
Long COVID is the consequence of having had COVID. Long COVID has many other names including Long-haul COVID, Post-COVID conditions (PCC), Post-COVID-19 syndrome, Post-acute seque...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

